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Background: With human papillomavirus (HPV) vaccination introduced in a number of countries, there is
considerable interest in evaluating the cost-effectiveness of HPV testing as the primary cervical screening test in
these settings. However, the availability of utility scores for these newer interventions is limited. Our aim in this
paper is to present utility scores for HPV vaccination, HPV testing and cytology based screening states among
women targeted for cervical screening.
Methods: We invited a random sample of women targeted for cervical screening (aged 20-69 years) living in
Sydney, Australia, to participate in a face-to-face interview. Participants were asked to indicate preferences (rank and
utility scores) for 10 hypothetical health states relating to HPV vaccination, cytology and primary HPV screening,
cervical precursor disease and early stage cervical cancer. Preferences for hypothetical health states were measured
through ranking then a two-stage standard gamble. Each participant’s own health state was measured as a utility
score using the EQ5D. Potential differences by age were assessed using the Wilcox Rank Sum test.
Results: A maximum of 276 women were contacted, of which 43 (mean age 49 years) agreed to be interviewed
(15.6%). The overall health state of women as measured by the EQ5D was 0.86 (95% CI: 0.83-0.89). Of the 10 health
states, the highest ranked were ‘normal cytology’ and ‘HPV vaccination’ (equal 1st). States involving an HPV positive
result with a subsequent normal cytology or colposcopy were ranked below those for low grade cytological
abnormalities with or without a subsequent colposcopic normal result (ranks 3-4 vs. 4-5). However, mean utility
scores were broadly similar for all health states, except cervical cancer. No significant differences in scores were
identified between age groups.
Conclusion: Our survey suggests health states relating to HPV testing are ranked below ‘low grade cytology’
disease abnormalities. However, this difference was minimal on the utility scale, as most values for health states
were largely clustered. These results provide a preliminary set of non-clinic population-based utilities that may be
used with other values to explore the economic implications of introducing HPV testing as a primary screening tool
in the context of HPV vaccination.
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Over the last six years, a number of developed countries
have introduced prophylactic vaccination against the
sexually transmitted human papillomavirus (HPV) in
pre-adolescent females. The decision to introduce HPV
vaccination has been supported by results from rando-
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unless otherwise stated.(conducted in the context of existing cytology based cer-
vical screening programs) [1]. At the same time, primary
HPV DNA testing has emerged as an alternative screening
technology to cervical cytology (‘Pap smears’), such that
several randomised controlled trials in Europe and North
America highlight higher sensitivity of primary HPV testing
(i.e. testing for a bank of oncogenic HPV types) for detect-
ing high grade precursor lesions (Cervical Intraepithelial
Neoplasia grades 2 and 3 and above; CIN2+ and CIN3+)
relative to cytology in baseline rounds of screening, with
lower rates of these high grade precursor cervical lesionsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lower rates of invasive cervical cancer in HPV-screened
women compared to cytology-screened women [5].
Due both to the emergence of these data on primary
HPV testing and to the implementation of HPV vaccin-
ation, a number of countries are formally evaluating a tran-
sition to primary HPV screening. Consequently, a number
of aspects of primary HPV testing will require detailed
evaluation in cost-effectiveness models; these include the
age range of women screened, the screening interval (in
vaccinated and unvaccinated women), the triaging and
management strategy for HPV-positive women, the role of
partial genotyping systems, and the role of adjunctive co-
testing (i.e. performing both HPV and cytology together at
the primary screening stage).
Historically, decision analytic models used to evaluate
the incremental cost-effectiveness of HPV vaccination in
the context of existing cervical cytology screening pro-
grams have adopted a specific set of health state prefer-
ence scores (utilities) to quantify the quality of life
effects associated with cervical screening and any de-
tected disease [7,8]. However, a limitation of these scores
is that they do not reflect the full complexity of health
states that women may experience, nor do they provide
preferences for interventions related specifically to pri-
mary HPV screening or HPV vaccination. Moreover, the
study underpinning these scores did not assess prefer-
ence across a representative age-sample of women tar-
geted for cervical screening. This is important because
the trade-off between benefits and harms of cervical
screening potentially differs substantially between youn-
ger and older (>45-50 years) women, since there are
some data to indicate that treatment for cervical precan-
cerous abnormalities increases the risk of subsequent ad-
verse obstetric outcomes in fertile women [9].
Our aim in this study was to estimate utility scores for
health states related to HPV vaccination, primary HPV
screening, cervical precursor disease and its treatment, and
early stage cervical cancer, among women aged 18-69 years,
which is the age group currently screened in Australia.
Methods
Study population
Participants were invited to participate via a regular
population health survey conducted by the New South
Wales (NSW) Department of Health, Australia [10,11].
The state based health survey invites residents to take
part in an over-the phone telephone interview. Partici-
pants are selected using a combination of random digit
dialling to select eligible inhabitants within specific
health service areas, followed by a letter of notification
[11,12]. Approximately 12,000 survey participants take
part in the health survey, representing a response rate of
63.4% [10]. Women invited to participate in the currentstudy were living in metropolitan Sydney and were within
the specified age groups (20-49 years and 50-69 years). If
the survey participant gave verbal consent, the NSW De-
partment of Health passed on their contact details to the
study investigators. Women aged 20-49 years were over-
sampled to enable appropriate representation in the survey.
Women in younger age groups are generally oversampled
due to their lower participation rate.
Health state scenarios
Ten hypothetical cervical cancer prevention health
states scenarios were evaluated in a face-to-face interview
(Table 1). Each scenario was described in a narrative for-
mat to explain the process of investigation and treatment
(if applicable), along with any physical and emotional con-
sequences (see Additional file 1) [13]. The scenario de-
scriptions were informed by relevant Australian screening
and treatment guidelines as well as the psychosocial litera-
ture [14-17]. As primary HPV testing is not yet commonly
used as part of routine screening in Australia, a scenario
was constructed based on a review of screening options
and quality of life assessments of experiences related to
HPV testing [18,19].
Overview of interview process
Interviews were undertaken by a single interviewer (LS).
After being given a brief description of the interview
process to enable informed consent, the participant was
provided with an explanation of concepts related to cer-
vical cancer, HPV, the HPV vaccine and other cervical
cancer prevention related activities, which was facilitated
with visual displays and incorporated an opportunity for
participants to ask questions. Participants then ranked
the description of each health state by selecting, at ran-
dom, one of the health states from the description vi-
gnettes; a second health state was then selected at
random and ranked relative to the first; this process was
continued until all ten health states were ranked relative
to each other (equal ranking was permitted). The utility
score for each of the 10 hypothetical health states was
assessed using a modified version of the standard gamble
(see below). The interview concluded by asking partici-
pants to document their age and own quality of life using
the EQ5D™ instrument. Questions regarding whether a
participant had experienced any of the health states was
not requested at any time during selection for participa-
tion or during the interview process.
Health state preference score assessment
A two-stage standard gamble was used to assess the utility
for each hypothetical health state. The assessment process
used two stages; Stage 1 derives probability indifference
scores (utilities) for each of the nine health states, mea-
sured relative to risky prospects between perfect health
Table 1 Summary of hypothetical scenarios used to evaluate cervical cancer prevention health states*
Health state Description (character name in health state description)
Cytology normal Pap test cytology negative (Kelly)
HPV vaccination Three doses of the HPV vaccine (Emily)
LG cytology Cytology screening with a low grade abnormality and a follow-up smear in 12 months (Lisa)
LG cytology with colposcopy
normal
Cytology screening with a low grade abnormality and immediate colposcopy (Andrea)
HPV positive with cytology
normal
HPV positive and cytology negative (to account for strategies involving either primary HPV screening with negative
cytology triage or primary co-testing with HPV and cytology) (Danielle)
HPV positive with
colposcopy normal
HPV oncogenic positive with an immediate colposcopy which has a normal result (to account for primary HPV
screening involving partial genotyping for HPV 16, 18 and immediate referral of this group) (Libby)
Treated genital warts Treatment for genital warts associated with HPV types 6 and 11 (Angela)
HG cytology with CIN 1 High grade abnormal cytology screening result with subsequent histologically-confirmed CIN Grade 1 (Natalie)
HG cytology with CIN 2 or 3 High grade abnormal cytology screening result with subsequent histologically-confirmed CIN Grade 2 or 3 (Deborah)
Early stage cervical cancer Early stage cervical cancer requiring a hysterectomy (Mary)
* HPV human papillomavirus; LG low grade disease; HG high grade disease; CIN cervical intraepithelial neoplasia; FIGO Fédération Internationale de Gynécologie
Obstétrique (International Federation of Gynecology and Obstetrics).
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probability indifference score for early stage cervical
cancer measured relative to the risky prospects associ-
ated with either perfect health or death (Figure 1) [20].
For stage 2, we evaluated cervical cancer twice using
two distinct ‘time in state’ scales (see below). Thus each
participant provided 11 health state preference scores;
nine for each temporary health state, two for early stage
cervical cancer. By valuing temporary health states that
do not involve any likely prospect of death (i.e. the
non-cancer states), ‘ceiling effects’ for the hypothetical
health states are potentially minimised [21]. The two-Figure 1 Conceptual outline of two-stage standard gamble.stage standard gamble has been adopted in previous as-
sessments of cervical cancer prevention [15,22,23].
For the temporary health states (non-cancer), partici-
pants were asked to imagine health returning to normal
after 12 months (Stage 1). For the cervical cancer health
state, where the probability of indifference between living
with early stage cervical cancer is measured relative to the
risky prospects associated with either perfect health or im-
mediate death (stage 2), two ‘time in state’ durations for
cervical cancer were used. The first was for 12 months
followed by sudden and painless death, the second ‘time in
state’ was to occur from the present until age 85 years
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was used to correspond with the duration of the tempor-
ary health states, as is required for the two-stage standard
gamble [20]. However, given women with early stage cer-
vical cancer are unlikely to die within 12 months, a more
clinical relevant duration was also used; that is, maximum
life expectancy. The use of two ‘time in state’ durations for
cervical cancer resulted in two sets of utility scores for
each hypothetical health state. Differences in health states
preference scores for each ‘time in state’ anchor point
would provide an indication of whether hedonic load
(period one has to live with the health state of interest) af-
fects utility scores.
To determine the utility score for temporary health
states on the 0 – 1 cardinal interval scale, the scores
were mathematically transformed using the following
function: hi = Pi + (1 − Pi)hk where hi is the utility of the
temporary health state, Pi is the probability of indiffer-
ence observed between the certain outcome of experien-
cing the temporary health state and the risky prospect of
either living with early stage cervical cancer or living
with perfect health, and hk is the utility of early stage
cervical cancer (worst health outcome) evaluated on the
death to perfect health scale [20]. Thus, for early stage
cervical cancer there are two hk; one evaluated on the 12
month time scale, and the other evaluated on the life
time scale. For each individual utility score representing
a temporary health state we applied two separate ‘time
in state’ values representing the anchor state (using the
mathematical function hi = Pi + (1 − Pi)hk. This resulted
in two distinct utility scores on the 0-1 cardinal interval
scale for each participant’s temporary health state, char-
acterised by the ‘time in state’ value; yielding 18 tempor-
ary health state utility scores for each participant.
Statistical analysis
Demographic characteristics (age and general health; as
indicated by the EQ5D) were reported using mean and
95% confidence intervals (95% CI). Each utility score
was summarised using the mean and standard error (SE)
as well as the median and inter-quartile range (IQR). An
intraclass correlation coefficient (ICC) was used to as-
sess the level of agreement between each participants’
pair of utility scores transformed with the 12 month dur-
ation for ‘early stage cervical cancer’ and the lifetime
duration [24]. The ICC was also used to measure the
level of agreement between the pair of ‘early stage cer-
vical cancer’ scores that were evaluated using the ‘12
month’ and ‘lifetime’ durations (‘time in state’ values).
The ICC is calculated as (MSbtw grps −MSwthin grps)/
(MSbtw grps +MSwthin grps); where MS refers to mean
square. In our analysis the MSbtw grps is characterised as
the difference between the grand mean for a health state
(combining both sets of utility scores calculated usingdifferent ‘time in state’ values) and the group means for
a health state calculated according for a specific ‘time in
state’ value. Whereas MSwthin grps is characterised as the
difference between the specific ‘time in state’ individual
utility scores and the mean of these scores. A low
MSwthin grps (relative to MSbtw grps) will provide an ICC
that is reasonable to good, whereas a high value will re-
sult in an ICC that is poor. For this analysis, we assumed
ICC values of 0.80–1.0 to have ‘good’ agreement. ICC
values between 0.50-0.80 were considered ‘reasonable’,
while those less than 0.50 were considered ‘poor’. To en-
able calculation of ICCs, one-way analysis of variance
(ANOVA) was carried out for each health state, such
that mean square values (‘between groups’ and ‘within
groups’) were determined for utility scores based on
each ‘time in state’ anchor state.
An exploratory analysis to assess differences in mean
utility scores for each temporary health state according
to age (20-49 years vs 50-69 years) was conducted using
the Wilcoxon Rank Sum Test [25]. Scores transformed
with ‘12 month’ and ‘lifetime’ durations were analysed
separately for each set of age group comparisons. Given
we are testing 10 distinct health states, with two sets of
‘time in state’ anchor states for the mathematical trans-
formation of temporary health states, a total of 20 tests
for statistical significance were made. Consequently, the
probability of making at least one ‘Type 1’ error (incor-
rectly rejecting a null hypothesis) is estimated to be
around 64% (calculated from 1 − (1 − α)m: where α is the
cut-off for statistical significance; 0.05, and m is the num-
ber of hypotheses tested; in this case 20), a Bonferroni cor-
rection of p < 0.003(defined as αmÞ was adopted as the ‘Type
I’ error cut-off threshold to evaluate any statistically-
significant difference between the age group for each utility
score. All analyses were conducted in EXCEL.Ethical approval
The study was approved by the Human Research Ethics
Committees of the University of Sydney and Cancer
Council NSW, Australia.Results
Study population
Recruitment for the study took place between 25 October
and 25 November 2010. A total of 276 eligible women
were identified and contacted by the NSW Department of
Health (Figure 2). Of these, 104 were aged 20-49 years,
and 172 aged 50-69 years. Of the 276 eligible women, 92
(33%) gave consent to pass on their contact details to the
investigators of which 37 were aged 20-49 years and 55
were aged 50-69 years. Of the 92 women who gave their
consent to pass on their contact details, 43 (46.7%) agreed
to participate.
Figure 2 Study participant flow chart - overall and by age group.
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were aged 50-69 years. The mean age of all participants
was 49.4 years (95% CI: 45.6–53.2 years) (Table 2).
Among the 20-49 year age group, the mean age was 38.2
years (95% CI: 34.6-41.8 years), while for the 50-69 year
age group it was 59.1 years (95% CI: 56.7-61.3 years).
The average overall EQ5D health score was 0.86 on the
0 to 1 scale of ‘worst imaginable health’ to ‘best imagin-
able health’ (95% CI: 0.83–0.89). The point estimate was
slighter higher among the younger age group (0.89, 95%
CI: 0.86–0.92) relative to the older age group (0.83, 95%
CI: 0.79–0.87) (Table 2).
Overview of health state preference scores
Of the 43 participants interviewed, two (one from each
age group) had difficulties with interpreting the standard
gamble process. Therefore, results presented here are for
the remaining 41 participants. The ordinal rank for each
of the health states is presented in Table 3. The highest
ranked health states were ‘Cytology normal’ and ‘HPV
vaccination’ (median rank; 1; IQR; 1-2), while the lowest
ranked was ‘early stage cervical cancer’ (median rank:
10; IQR: 8-10).Table 2 Health state evaluation measured using the
EQ5D in the study population (mean and 95% confidence
intervals)
Characteristic Overall 20-49 years 50-69 years
Age (years) 49.4 38.2 59.1
(45.6-53.2) (34.6-41.8) (56.7-61.3)
Overall health* 0.86 0.89 0.83
(worst ‘0’ - best ‘1’ health) (0.83-0.89) (0.86-0.92) (0.79-0.87)Pap tests, HPV testing and HPV vaccination
Across the numerical descriptions of utility scores for
each health state (‘12 month’ duration, mean; ‘12 month’
duration, median; ‘lifetime’ duration, mean; ‘lifetime’
duration, median), a ‘normal cytology result’ had a nar-
rower range of utility scores compared with ‘HPV vac-
cination’ (0.9967 to 1.0 vs 0.9750 to 1.0), indicating
greater heterogeneity in the evaluation of HPV vaccin-
ation state compared to the state relating to an experi-
ence of being screened with a normal cytology result
(Table 3). For investigations involving an HPV test, a
‘positive for HPV infection with a normal cytology re-
sult’ had a lower range of preference scores relative to
the health state described as ‘positive for HPV infection
with a colposcopy normal result’ (0.9733 to 1.0 vs 0.9964
to 0.9999), indicating that more intensive investigations
(colposcopy) resulted in higher utility scores.Low grade disease and genital warts
The health states described as ‘low grade cytology’ and
‘low grade cytology with a normal colposcopy result’ had
similar ranges of scores (0.9735 to 1.0 vs 0.9724 to
0.9999) (Table 3). Although the state reflecting a high
grade cytology result with subsequent confirmed CIN 1
involved an initial report of high grade cytology, on aver-
age, study participants assessed this to have the same
utility score as a ‘low grade cytology with a normal col-
poscopy result’ (0.9724 to 0.9999 vs 0.9724 to 0.9999)
(Table 3). The health state ‘treated genital warts’ had
slightly lower range of health state preference score rela-
tive to the low grade disease health states (0.9700 to
0.9998).

















coefficient(IQR ) (SE) (IQR) (SE) (IQR)
Cytology normal
1 0.9967 0.9998 0.9995 1.0
0.13(1-2) (0.0026) (0.9994 - 1.0) (0.0002) (0.9998 -1.0)
HPV vaccination
1 0.9750 0.9998 0.9978 1.0
0.07(1-2) ( 0.0244) (0.9996 - 1.0) (0.0018) (0.9998 - 1.0)
LG cytology
3 0.9735 0.9997 0.9980 1.0
0.05(3-5) (0.0231) (0.9994 - 1.0) (0.0017) (1.0 -1.0)
LG cytology with colposcopy normal
4 0.9724 0.9997 0.9970 0.9999
0.08(3-6) (0.0226) (0.9964 - 0.9999) (0.0017) (0.9997 - 1.0)
HPV positive with cytology normal
4 0.9733 0.9997 0.9970 0.9999
0.02(3-6) (0.0233) (0.9977 - 0.9999) (0.0017) (0.9997 - 1.0)
HPV positive with colposcopy
normal
5 0.9964 0.9997 0.9991 0.9999
0.22(3-6) ( 0.0021) (0.9984 - 0.9999) (0.0004) (0.9997 - 1.0)
Treated genital warts
5 0.9700 0.9997 0.9969 0.9998
0.09(3-7) ( 0.0244) (0.9969 - 0.9999) (0.0019) (0.9997 - 1.0)
HG cytology with CIN 1
6 0.9724 0.9997 0.9953 0.9999
0.01(4-8) (0.0226) (0.9970 - 0.9999) (0.0027) (0.9997 - 1.0)
HG cytology with CIN 2 or 3
7 0.9704 0.9996 0.9970 0.9999
0.12(6-9) (0.0233) (0.9959 - 0.9999) (0.0018) (0.9994 - 1.0)
Early stage cervical cancer
10 0.8178 0.9450 0.9714 0.9900
0.78(8-10) (0.0531) (0.915 - 0.995) (0.0052) (0.9450 - 0.9950)
HPV human papillomavirus; LG low grade disease; HG high grade disease; CIN cervical intraepithelial neoplasia; FIGO Fédération Internationale de Gynécologie
Obstétrique (International Federation of Gynecology and Obstetrics.
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The utility scores for ‘high grade cytology with con-
firmed CIN 2/3’ ranged from 0.9704 to 0.9999. The
mean values for this health state (transformed using the
‘12 month-early stage cervical cancer’ score) were similar
to the health state ‘treated genital warts’ (0.9704 vs
0.9700). Similarly, mean utility scores (transformed using
the ‘lifetime duration-early stage cervical cancer’ score)
were the same for a ‘low grade cytology with a normal
colposcopy result’ and ‘positive for HPV infection with a
normal cytology result’ (0.9970). The health state ‘early
stage cervical cancer’ had the lowest utility score when
assessed using 12 month ‘time in state’ (mean: 0.8178;
SE: 0.05314, median: 0.9450; IQR: 0.9150-0.9950) com-
pared with lifetime ‘time in state’ (mean: 0.9714; S.E:
0.005217, median: 0.9900; IQR: 0.9450-0.9950).
The intraclass correlation coefficient indicated reason-
able agreement for ‘early stage cervical cancer’ utility
scores assessed using a ‘12 month’ duration and a ‘life-
time’ duration (ICC: 0.78) (Table 3). By contrast, thelevel of agreement between non-cervical cancer health
states converted on the 0-1 cardinal scale using the ‘12
month’ and ‘lifetime’ duration cervical cancer preference
score was generally poor. These ranged from 0.01 (high
grade cytology with confirmed CIN 1) to 0.22 (HPV posi-
tive with normal subsequent colposcopy). However, the
absolute differences between the mean utility scores be-
tween each health state were small. For ‘high grade cy-
tology with confirmed CIN 1: 0.9724 (using the 12 month
duration cervical cancer value) minus 0.9953 (using the
lifetime duration cervical cancer) equates to an absolute
difference of 0.0229. For HPV positive with normal subse-
quent colposcopy the absolute difference was 0.0027.
Utility scores transformed using ‘12 month-early stage
cervical cancer’ suggested no significant difference be-
tween women aged 20–49 and 50–69 years when assessed
using the Wilcoxon Rank Sum Test (Tables 4 and 5). A
similar pattern was observed for age group comparisons
between utility scores transformed with ‘lifetime duration-
early stage cervical cancer’ (Table 4).







20-49 years 50-69 years
Mean utility score Median utility score (IQR) Mean utility score Median utility score
(SE) (SE) (IQR)
Cytology normal
0.9938 0.9997 0.9990 0.9999
0.4932(0.0055) (0.9994 - 1.0) (0.0004) (0.9994 - 1.0)
HPV vaccination
0.9992 0.9998 0.9539 1.0
0.6534( 0.0004) (0.9994 - 1.0) ( 0.0454) (0.9996 - 1.0)
LG cytology
0.9935 0.9997 0.9563 0.9998
0.2855(0.0055) (0.9993 - 0.9999) (0.0429) (0.9996 - 1.0)
LG cytology with colposcopy normal
0.9909 0.9997 0.9563 0.9997
0.3383(0.0070) (0.9950 - 0.9999) (0.0420) (0.9969 - 1.0)
HPV positive with cytology normal
0.9942 0.9997 0.9552 0.9997
0.3379(0.003955) (0.9959 - 0.9999) ( 0.0434) (0.9977 - 1.0)
HPV positive with colposcopy normal
0.9934 0.9997 0.9990 0.9998
0.1280( 0.0045) (0.9950 - 0.9999) (0.0004) (0.9989 - 0.9999)
Treated genital warts
0.9894 0.9997 0.9532 0.9997
0.2483( 0.0056) (0.9950 - 0.9999) ( 0.0454) (0.9990 - 1.0)
HG cytology with CIN 1
0.9956 0.9997 0.9523 0.9996
0.3725( 0.0024) (0.9950 - 0.9997) (0.0420) (0.9977 - 0.9999)
HG cytology with CIN 2 or 3
0.9908 0.9995 0.9527 0.9996
0.2826(0.0049) (0.9948 - 0.9997) (0.0433) (0.9983 - 1.0)
Early stage cervical cancer
0.7977 0.9450 0.8352 0.960
0.2616(0.0819) (0.8850 - 0.9750) (0.0709) (0.915 - 0.995)
HPV human papillomavirus; LG low grade disease; HG high grade disease; CIN cervical intraepithelial neoplasia; FIGO Fédération Internationale de Gynécologie
Obstétrique (International Federation of Gynecology and Obstetrics.
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This study is the first of its kind to assess cervical cancer
prevention utility scores in a random sample of women
from the general population (non-clinic based popula-
tion) targeted for cervical screening. We assessed 10
hypothetical health states that include experiences for
important future cervical screening strategies in an era
of HPV vaccination that will potentially involve primary
HPV testing. Although the sample size of the study was
relatively small, we have generated a preliminary set of
health state utilities that can be used to inform detailed
cost-effectiveness evaluation of primary HPV testing,
HPV testing with genotyping, co-testing, and cytology
triage after HPV positive testing, in the context of the ef-
fect of HPV vaccination.
The utility scores for health states obtained in the current
study that described the experience of having a normal cy-
tology result and low grade cervical disease (with/without
colposcopy) appeared to be similar to other studies which
measured similar health states [7,8,15,22,23,26]. For the
health state of ‘a normal pap test result’, Kupperman et al.
estimated a mean and median score of 0.989 and 1.0,respectively for women who were treated for a cervical ab-
normality [26], using a time trade-off instrument. This was
broadly comparable to the range utility scores obtained in
this study (0.9967 to 1.0). For low grade cytology (without
colposcopy) the range of utility scores was between 0.9735
to 1.0, which were similar to a previous ‘two-stage standard
gamble’ assessment conducted among women recruited
through pharmacy and general practitioner clinics in
Sydney, Australia (mean: 0.9972 and median: 0.9963)
[15]. However, the values obtained in the current study
were higher than from a study in family planning clinics in
California (mean: 0.96) and a commonly used set of util-
ities from a study at Duke University hospital clinic (mean:
0.91 – it was assumed the reported score was a mean as
opposed to median) [7,8,22]. It should be noted however,
that the study in California involved hypothetical scenarios
that involved repeated visits and additional smears and
colposcopy, which may have influenced the values ob-
tained, but it is not certain how scenarios were described
since detailed vignette descriptions were not given.
For the cervical cancer health state measured in the
current study, the range of utility scores obtained was







20-49 years 50-69 years
Mean utility score Median utility score Mean utility score Median utility score
(SE) (IQR) (SE) (IQR)
Cyto normal
0.9996 1.0 0.9994 0.9999
0.9255(0.0002) (0.9997 -1.0) (0.0003) (0.9998 -1.0)
HPV vaccination
0.9998 1.0 0.9960 1.0
0.8408(<0.0000) (0.9998 - 1.0) (0.0034) (0.9998 - 1.0)
LG cyto
0.9996 1.0 0.9965 1.0
0.8174(0.0002) (0.9997 -1.0) (0.0032) (1.0 -1.0)
LG cyto with colp normal
0.9985 0.9999 0.9956 0.9999
0.8933(0.0086) (0.9996 - 1.0) (0.0032) (0.9997 - 1.0)
HPV positive with cyto normal
0.9986 0.9999 0.9956 0.9999
0.786(0.0009) (0.9997 - 1.0) (0.0032) (0.9997 - 1.0)
HPV positive with colp normal
0.9987 0.9999 0.9994 1.0
0.2892(0.0009) (0.9997 - 1.0) (0.0003) (0.9998 - 1.0)
Treated genital warts
0.9983 0.9998 0.9957 0.9999
0.8211(0.0010) (0.9994 - 1.0) ( 0.0034) (0.9997 - 1.0)
HG cyto with CIN 1
0.9989 0.9999 0.9922 0.9998
0.8517(0.0007) (0.9996 - 0.9999) (0.0045) ( 0.9997 - 1.0)
HG cyt with CIN 2 or 3
0.9983 0.9997 0.9954 0.9999
0.8733(0.0010) (0.9994 - 0.9998) (0.0033) (0.9992 - 1.0)
Early stage cervical cancer
0.9732 0.9950 0.9697 0.9850
0.4817(0.0085) (0.9550 - 0.9950) (0.0066) (0.9450 - 0.9950)
HSPS health state preference score; Cyto cytology; HPV human papillomavirus; LG low grade disease; HG high grade disease; Colp colposcopy; CIN cervical intraepithelial
neoplasia; FIGO Fédération Internationale de Gynécologie Obstétrique (International Federation of Gynecology and Obstetrics).
Simonella et al. BMC Research Notes 2014, 7:899 Page 8 of 11
http://www.biomedcentral.com/1756-0500/7/899between 0.8178 to 0.9900. These were similar to scores
obtained from another study of women who underwent
prior treatment for any abnormal cervical disease (mean
0.816 and median 0.972) [26]. By contrast, the range of
health state preference scores for the health state ‘high
grade cytology with a confirmed CIN 2/3’ obtained in
this study (0.9704 to 0.9999) were significantly higher
than those obtained from women who had a previous
history of treatment for any cervical abnormality (mean:
0.835 and median: 0.984) and from women recruited for
the Myers et al. study at Duke University hospital clinic
(mean score for high grade squamous intraepithelial le-
sion: 0.91; mean score for CIN 2/3: 0.87 - it was as-
sumed mean scores were reported) [7,8,26].
In the assessment of cervical cancer prevention health
states, the use of the ‘two-stage standard gamble’ in-
volves a shift in endpoints, that is, from the worst an-
chor state of ‘death’ to ‘early stage cervical cancer’.
Therefore, in using our approach, a key assumption is
that participants are able to shift the interpretation of
the scale end points from the ‘early stage cervical cancer’
(low end) to ‘perfect health’ (high end) scale, to the‘death’ (low end) to ‘perfect health’ (high end) scale [27].
If participants do not shift their endpoints in an evalu-
ation, that is, they maintain the same risk attitude for as-
sessments of non-cervical cancer health states towards
the assessment of cervical cancer, the transformed health
state preference score for non-cervical cancer health
states will appear artificially high. Stalmeier has shown
that when the worst anchor point has shifted, that is
from ‘death’ to a worst temporary health state, the math-
ematically transformed health state preference score (as
described and used in this study) produced higher out-
comes compared with the conventional single stage as-
sessment [27]. Given this observed phenomena in
previous studies, it is possible that a potential lack of
end-point adjustment by participants in the current
study could explain the higher utility scores for some of
the assessed health states, especially for the management
of high grade disease.
In our study we observed that the two-stage standard
gamble produced utility scores for health states that were
generally lower when reported as means than when re-
ported as medians. For example, the early stage cervical
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mean (using ‘12 month’ time-in-state duration), whereas a
median value indicated an average score of 0.9450. The
reason for this is likely to reflect the small sample size and
the wide distribution of scores. In this context, values that
tend towards the lower end of a distribution are likely to
pull the mean estimate down, whereas the median is not
so affected by ‘outlier’ values.
The mean score can diverge from the median if there
are a group of participants in the study sample who
value an experience lower than other groups (due, for
example to particular levels of underlying anxiety). For
cost-effectiveness analysis, mean scores have been advo-
cated by some health economists as they indicate the
group strength of preference for a health state [21]. By
contrast, the median value treats each health state valu-
ation equally in a voting context and is less likely to be
influenced by extreme values or outliers [21]. The deci-
sion to use either the mean or median is a matter of de-
bate and thus different primary studies have used
different methods [21]. Therefore, for interventions that
are being evaluated for cost-effectiveness using decision
analytic modelling, an array of health state preference
scores needs to be assessed in order to determine
whether the cost per QALY is affected by the choice of
health state preference scores.
We also attempted to address the issue of whether dif-
ferent ‘time in state’ values for an anchor state used in a
two-stage standard gamble has the potential to affect
utility scores for temporary health states. Our results
suggest that, according to the ICC values, there is the
potential for ‘time in state’ to distort utility scores for
temporary health states. On the other hand, this finding
may be due to the small sample size obtained for our
study. In the calculation of MSwthin grp values, differences
between individual utility scores and their mean can be
large enough so as to provide a value that is similar to
the respective MSbtw grp value; where the latter is based
on the difference between two sets of utility scores (the
mean of each ‘time in state’ specific health state utility
score) and their (grand/overall) mean. Thus in the con-
text of a small study, only a handful of larger differences
between individual utility scores and their mean is re-
quired for an observation such as ours. However, a visual
inspection of mean values for each set of temporary
health states suggests that the differences in the utility
scores are minor. Nonetheless, our findings do not pre-
clude the need for such an issue to be investigated in the
future. If ‘time in state’ values do have the potential to
distort utility scores for temporary health states, this
needs to be addressed appropriately in techniques that
use ‘time in state’ (time-trade off ) to derive utilities.
The limited number of women recruited into the study
has the potential to affect the generalizability of ourresults. We sought to recruit women eligible for cervical
screening in Australia (aged 18-20 to 69 years). This was
done through recruiting a random sample of women liv-
ing in metropolitan Sydney. However, given only 15.6%
of women contacted agreed to be interviewed, there is
the possibility that those who did not participate may
have demographic, cultural, medical and/or lifestyle
characteristics that are distinct from the sample obtained
in this study. Selection bias refers to systematic error in
the way women are recruited into the study. However,
the NSW Department of Health Population Survey, from
which our study participants were recruited, utilizes ro-
bust random sampling techniques to ensure the results
of the survey accurately reflects the population of New
South Wales. Thus, if the results of our survey are to be
applied in cost-effectiveness analyses, they should be
used in conjunction with other sources of health state
preference scores so as to ensure a robust sample of
women are represented from the population of interest.
Stated preferences for health states for cervical cancer
prevention may be affected by the participant’s age at
which the assessment is done. Such differences may
occur, for example, for cervical screening with cytology,
where a younger women, who may not have had a pap
smear, could be more fearful of the procedure compared
to an older women who has undergone the procedure
on a regular basis. Consequently, the utility score at-
tached to a health state may be lower amongst those
who younger in the study population, relative to those
who are older. As part of our analysis we explored
whether this particular phenomena may occur amongst
women aged 20-49 years relative to women aged 50-69
years. Our results did not find a statistically significant
difference in the values attached to health states for cer-
vical cancer between the two age groups. However, given
our study was not powered to detect differences between
these groups, the conclusion regarding this finding re-
mains uncertain and requires further testing.
Differences between the rank of measured health state
preference scores and those of ranking health states
alone can potentially be explained by the instruments
used; standard gamble versus ranking. The standard
gamble utilises the notions of choice and uncertainty to
evaluate health state preference values; whereas ranking
is based on certainty of outcome in the absence of
choice. Consequently, ranking does not reflect how deci-
sions are made in the real world and are not considered
reasonable proxies for estimating cardinal utility of
health states. In our study, the ranking process required
participants to focus on aspects of process, such as going
through a colposcopy procedure. This state is ranked
relative to other states. However, for the standard gam-
ble participants are given a choice and are faced with the
possibility of being diagnosed with cervical cancer if they
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poscopy may have been seen as an acceptable process to
confirm the absence of disease, which could have been
perceived as worthwhile, when compared to the probabil-
ity of being diagnosed with cervical cancer. Therefore, the
methods used to compare health state scenarios can influ-
ence the values assigned and the relative ranking of health
states.
The utility set generated from the current study has
already been employed in a supplementary analysis of
QALYs performed as part of an evaluation of the cost-
effectiveness of primary HPV testing in England [28] and
Australia [29], and the utility set is also currently being
used for similar supplementary analyses in government-
commissioned assessments of primary HPV screening in
Australia and New Zealand. Investigation of utilities related
to primary HPV screening is a major research need in cer-
vical cancer prevention policy evaluations since the choice
of utility values has a considerable effect on the outcomes
of such cost-effectiveness evaluations [29]. We have found,
for example, that attaching a disutility to a screening test
with a normal result (which can be broadly interpreted as
‘the experience of being screened’) has a profound impact
on the relative cost-effectiveness of cervical screening strat-
egies with different screening frequencies, as is the case for
cytology vs. primary HPV strategies. Furthermore, because
the values identified in the current study are associated
with far less disutility (higher utility values) for diagnosis
and management of screen-detected high grade abnormal-
ities compared to the most commonly utilised set [7,8], our
findings potentially have important implications for the
relative evaluation of different cervical screening technolo-
gies because different technologies are associated with dif-
ferent rates of high grade abnormalities in the population
(due both to varying test characteristics and to the differing
frequency of screening). Our findings for the disutilities as-
sociated with high grade abnormalities also have the poten-
tial to impact the evaluation of the relative benefits of
vaccination and screening and thus the evaluation of the
cost-effectiveness of vaccination itself (since vaccination in
a cohort reduces the number of screen-positive events and
their downstream sequelae experienced by that cohort).Conclusion
Our survey suggests health states relating to HPV testing
are ranked lower than low grade cytology disease abnor-
malities. However, this did not translate into large differ-
ences in utility scores. Although in this initial assessment
our sample size was limited, these results provide a pre-
liminary set of population-based values (non-clinic) that
may be used with other utility scores to explore the eco-
nomic implications of introducing HPV testing as a pri-
mary screening tool in the context of HPV vaccination.Additional file
Additional file 1: Health state vignettes.
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